Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (731-740 of 849) with videos related to

Pageof 85
Sort By:
Iscience|December 11, 2024
Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosisRoman N Rodionov, Natalia Jarzebska, Yen Chin Koay, et al.
JHEP Reports : Innovation in Hepatology|September 11, 2023
Type 2 innate lymphoid cells are protective against hepatic ischaemia/reperfusion injuryQi Cao, Ruifeng Wang, Zhiguo Niu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2021
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver diseaseStefania Grimaudo, Paola Dongiovanni, Jussi Pihlajamäki, et al.
Circulation. Cardiovascular Genetics|August 10, 2017
<i>CKM</i> Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With MyalgiaMoneeza Kalhan Siddiqui, Abirami Veluchamy, Cyrielle Maroteau, et al.
Gastroenterology|May 16, 2006
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient dataGioacchino Leandro, Alessandra Mangia, Jason Hui, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|July 10, 2025
Intravascular brachytherapy versus drug-coated balloons for in-stent restenosis: A two-center two-strategy comparisonGal Sella, Gera Gandelman, Alex Blatt, et al.
Alimentary Pharmacology & Therapeutics|April 12, 2019
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levelsAmanda J Nicoll, Stuart K Roberts, Ricky Lim, et al.
Plos One|December 11, 2020
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver diseaseAli Bayoumi, Ismail Jalil, Mayada Metwally, et al.
Journal of Gastroenterology and Hepatology|December 19, 2023
Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of carePaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Frontiers in Cardiovascular Medicine|January 28, 2026
Intravascular brachytherapy vs. drug-coated balloons for in-stent restenosis in patients with diabetesGal Sella, Gera Gandelman, Alex Blatt, et al.
Pageof 85

Showing results (731-740 of 849) with videos related to

Sort By:
Pageof 85
Iscience|December 11, 2024
Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosisRoman N Rodionov, Natalia Jarzebska, Yen Chin Koay, et al.
JHEP Reports : Innovation in Hepatology|September 11, 2023
Type 2 innate lymphoid cells are protective against hepatic ischaemia/reperfusion injuryQi Cao, Ruifeng Wang, Zhiguo Niu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2021
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver diseaseStefania Grimaudo, Paola Dongiovanni, Jussi Pihlajamäki, et al.
Circulation. Cardiovascular Genetics|August 10, 2017
<i>CKM</i> Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With MyalgiaMoneeza Kalhan Siddiqui, Abirami Veluchamy, Cyrielle Maroteau, et al.
Gastroenterology|May 16, 2006
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient dataGioacchino Leandro, Alessandra Mangia, Jason Hui, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|July 10, 2025
Intravascular brachytherapy versus drug-coated balloons for in-stent restenosis: A two-center two-strategy comparisonGal Sella, Gera Gandelman, Alex Blatt, et al.
Alimentary Pharmacology & Therapeutics|April 12, 2019
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levelsAmanda J Nicoll, Stuart K Roberts, Ricky Lim, et al.
Plos One|December 11, 2020
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver diseaseAli Bayoumi, Ismail Jalil, Mayada Metwally, et al.
Journal of Gastroenterology and Hepatology|December 19, 2023
Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of carePaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Frontiers in Cardiovascular Medicine|January 28, 2026
Intravascular brachytherapy vs. drug-coated balloons for in-stent restenosis in patients with diabetesGal Sella, Gera Gandelman, Alex Blatt, et al.
Pageof 85